Back to Peptipedia
Basic research & contextPreclinical

Livagen

Lys-Glu-Asp-Ala (KEDA)

Livagen is a synthetic tetrapeptide with ex-vivo and in-vitro findings; clinical liver or anti-aging benefit is not established.

Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.

Research areas

Source-based short profile

Evidence matrix

Molecular identity
Confirmed

The cited primary literature defines Livagen as Lys-Glu-Asp-Ala. This identity applies to the studied synthetic peptide, not automatically to same-named products or extracts.

Human research
None
Replication
Single research group
Clinical endpoints
No clinical endpoints
Safety
Not adequately studied
Approval
No documented approval

The dimensions are presented separately and are not combined into an overall score.

What the source shows

The experiments occurred outside the body. The chromatin report used lymphocytes from older donors, not clinical liver endpoints.

Research gaps

  • ·No clinical evidence of liver rejuvenation is established here. The work comes from a narrow research network and provides no independent clinical replication.
  • ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.